On July 22, 2026, Dr. Reddy’s reported its first quarter earnings results for fiscal year 2027, revealing an earnings miss and disclosing a ?2.4 billion provision tied to out-of-spec semaglutide batches. Chief Executive Officer Erez Israeli stated there was “no impact on the product’s existing global regulatory filings” and “no patient-safety impact associated with product already supplied to the market.”
On this news, the price of Dr. Reddy’s ADSs fell $1.17 per ADS, or 9%, to close at $11.30 on July 22, 2026.